Blocking Antibody Is Generated in Allergic Rhinitis Patients during Specific Immunotherapy Using Standardized Japanese Cedar Pollen Extract

Background: Japanese cedar pollen is by far the most important cause of allergic rhinitis in Japan. In this study, we assessed the induction of blocking antibody during specific immunotherapy (SIT) using a recently standardized allergen extract from Japanese cedar pollen. Methods: Basophils from nonallergic subjects were passively sensitized with serum samples prepared from pollinosis patients before and after SIT; all patients showed good clinical efficacy. The cells were then stimulated with the standardized allergen, and histamine release was measured. In most experiments, the basophil stimulation buffer contained 1% serum. Results: Pollinosis patients’ sera obtained both before and after SIT showed essentially similar sensitizing capacity for basophils. Basophil degranulation in response to a relatively low concentration of pollen extract was effectively suppressed by addition of post-SIT serum samples, indicating the presence of blocking antibody. The blocking antibody was IgG, and its potency varied widely among the donor patients. Conclusions: The standardized allergen extract from Japanese cedar pollen is useful not only for clinical application in SIT, but also for testing for induction of blocking antibody during SIT.

[1]  M. Nagao,et al.  Allergen-Induced Basophil CD203c Expression as a Biomarker for Rush Immunotherapy in Patients with Japanese Cedar Pollinosis , 2008, International Archives of Allergy and Immunology.

[2]  T. Nito,et al.  Ortho-phthalaldehyde-induced anaphylaxis after laryngoscopy. , 2006, The Journal of allergy and clinical immunology.

[3]  Y. Kaneko,et al.  Increasing Prevalence of Japanese Cedar Pollinosis: A Meta-Regression Analysis , 2005, International Archives of Allergy and Immunology.

[4]  M. Dallman,et al.  Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease , 2004, The Lancet.

[5]  S. Durham,et al.  Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. , 2003, The Journal of allergy and clinical immunology.

[6]  Marek Jutel,et al.  IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy , 2003, European journal of immunology.

[7]  K. Ohta,et al.  Induction of Basophil Desensitization in Physiological Medium: Enhancement after IgE-Dependent Upregulation of Surface IgE Binding on Basophils , 2003, International Archives of Allergy and Immunology.

[8]  Erkka Valovirta,et al.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). , 2002, The Journal of allergy and clinical immunology.

[9]  N. York,et al.  Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six‐year follow‐up study. , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[10]  R. Merendino,et al.  Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[11]  S. Durham,et al.  Allergen immunotherapy: does it work and, if so, how and for how long? , 2000, Thorax.

[12]  I. Moro,et al.  Secretory IgA induces degranulation of IL-3-primed basophils. , 1998, Journal of immunology.

[13]  S. Durham,et al.  Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. , 1996, The Journal of allergy and clinical immunology.

[14]  M. Sakaguchi,et al.  [Guidelines for standardization of allergens and cedar pollen allergen extract in Japan]. , 1996, Arerugi = [Allergy].

[15]  K. Akiyama,et al.  [An enzyme-linked immunosorbent assay (ELISA) for the quantitation of sugi pollen and Dermatophagoides mite allergens and its application for standardization of allergen extracts]. , 1991, Arerugi = [Allergy].

[16]  L. Lichtenstein,et al.  A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. , 1968, Journal of immunology.

[17]  M. Loveless Immunological Studies of Pollinosis: I. The Presence of Two Antibodies Related to the Same Pollen-Antigen in the Serum of Treated Hay-Fever Patients , 1940, The Journal of Immunology.

[18]  R. Cooke,et al.  SEROLOGICAL EVIDENCE OF IMMUNITY WITH COEXISTING SENSITIZATION IN A TYPE OF HUMAN ALLERGY (HAY FEVER) , 1935, The Journal of experimental medicine.

[19]  Y. Nakai,et al.  Pollen immunotherapy inhibits T helper 1 and 2 cell responses, but suppression of T helper 2 cell response is a more important mechanism related to the clinical efficacy. , 2000, Archives of otolaryngology--head & neck surgery.